tiprankstipranks
Akari Therapeutics (AKTX)
NASDAQ:AKTX
US Market

Akari Therapeutics (AKTX) Income Statement

Compare
284 Followers

Akari Therapeutics Income Statement

Last quarter (Q3 2024), Akari Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Akari Therapeutics's net income was $-2.90M. See Akari Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
----$ -19.20K
Operating Expenses
$ 16.81M$ 23.89M$ 17.21M$ 20.10M$ 24.89M
Depreciation and Amortization
$ 4.00K---$ 19.20K
EBITDA
$ -16.80M$ -23.08M$ -17.21M$ -20.44M$ -24.73M
Operating Income
$ -16.81M$ -23.09M$ -17.21M$ -17.98M$ -24.87M
Other Income/Expenses
$ 6.80M$ 5.34M$ -210.10K$ 899.36K$ -142.67K
Pretax Income
$ -10.01M$ -17.75M$ -17.42M$ -20.45M$ -24.75M
Net Income
$ -10.01M$ -6.97M$ -17.61M$ -17.60M$ -21.76M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -2.04$ -2.23$ -8.20$ -11.14$ -23.77
Diluted EPS
$ -2.04$ -2.23$ -8.20$ -11.14$ -23.77
Weighted Average Shares Outstanding
4.89M 3.12M 2.15M 1.58M 915.50K
Weighted Average Shares Outstanding (Diluted)
4.89M 3.12M 2.15M 1.58M 915.50K
Currency in USD

Akari Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis